PetDx – The Liquid Biopsy Company for Pets has released a white paper demonstrating that OncoK9, its pioneering multi-cancer early detection (MCED) test for dogs, can enhance cancer monitoring in canine patients with a simple blood draw. The CANcer Detection in Dogs (CANDiD) study previously established the performance characteristics of the OncoK9 test for detection of 30 different types of canine cancer using next-generation sequencing (NGS) of blood-derived DNA. Initially recommended for cancer screening and as an aid-in-diagnosis, OncoK9® – The Liquid Biopsy Test for Dogs™ is now also recommended for detection of residual disease and detection of recurrence in dogs previously diagnosed with cancer.

“It is an exciting development for the field to have a non-invasive cancer detection test that can alert the veterinarian to the presence of residual disease following surgery, or to disease recurrence following therapy,” said Angela McCleary-Wheeler, DVM, PhD, DACVIM (Oncology), Director of Translational Research and Collaboration at PetDx. “It is important to note that this test is intended to be used as an adjunct tool for cancer monitoring in dogs; it does not replace standard-of-care clinical assessment methods.”

Following therapeutic intervention for cancer, veterinarians typically perform physical examinations and imaging tests to evaluate the clinical disease status at follow-up visits. Unfortunately, these tools may not be sensitive enough to detect residual disease after surgery or early evidence of cancer recurrence following therapy. Further, access to some imaging methods may be limited, pose risks to patients, or both.

As part of the clinical research program that supported the CANDiD study, longitudinal blood samples were collected from over 200 cancer-diagnosed canine patients across more than 500 follow-up visits to evaluate the performance of the OncoK9 test for cancer monitoring in the post-diagnosis setting.

“In human oncology, blood-based detection of cancer signal after therapeutic intervention has been shown to be an effective prognostic marker and recurrence predictor and has been deployed in routine clinical care for multiple cancer types. For the first time, we present analogous results in the veterinary medicine setting, based on the largest canine cancer cohort with longitudinal monitoring by liquid biopsy reported to date,” said Dana Tsui, PhD, PetDx Chief Scientific Officer. “We are excited to take OncoK9 one step further to not only help detect cancer earlier in dogs but to also help veterinarians monitor the disease more effectively after it has been diagnosed, with the convenience of a simple blood draw.”

Source: Company Press Release